Stanford Researchers Find a Way to Regenerate Cartilage and Potentially End the Era of Joint Replacement

Scientists at Stanford Medicine have published research in the journal Science (November 27, 2025) demonstrating that blocking a single aging-related protein can reverse cartilage loss in aging mouse joints and prevent arthritis from developing after knee injuries. The same approach also triggered cartilage regeneration in human tissue taken from knee replacement surgeries, pointing toward a future therapeutic strategy that could, if validated in clinical trials, replace joint replacement surgery as the primary intervention for osteoarthritis.

The protein at the center of this research is called 15-PGDH, identified by the researchers as a gerozyme, a class of proteins that increase in prevalence as the body ages and drive the gradual loss of tissue function. The concept of gerozymes was developed by the same Stanford team in 2023. In the context of joint cartilage, 15-PGDH levels roughly double between young and old mice. When the enzyme is active, it breaks down prostaglandin E2, a molecule essential for tissue repair and stem cell function across multiple tissue types.

The researchers found that injecting aged mice with a small molecule inhibitor of 15-PGDH produced dramatic regeneration of knee cartilage. Treated aged mice showed cartilage tissue that visually and functionally resembled that of young, healthy mice. They moved more normally, placed more weight on their legs, and demonstrated improved gait. In mice with knee injuries resembling ACL tears, repeated injections significantly reduced the likelihood of osteoarthritis developing. Untreated animals developed arthritis within four weeks. Treated animals avoided this outcome and bore more weight on the injured limb.

Perhaps most significantly for translational prospects, cartilage samples taken from patients undergoing total knee replacement surgeries were exposed to the 15-PGDH inhibitor. The human tissue displayed reduced degradation signals and began generating new articular cartilage. The cartilage produced was genuine hyaline cartilage, the smooth, functional type found in healthy joints, not the inferior fibrocartilage that forms as scar tissue after most current repair procedures.

The mechanism uncovered by the researchers is also notable for what it does not involve. Cartilage has long been considered one of the least regenerative tissues in the body, largely because it lacks the stem cell populations found in other tissues. The Stanford team found that 15-PGDH inhibition triggers existing cartilage cells, the chondrocytes, to change their gene expression patterns, reverting toward a more youthful state that enables repair. No new cells are introduced. The existing cells are reprogrammed.

A small molecule that can be delivered orally or by local injection and that triggers regeneration through existing cells is a fundamentally more accessible and scalable approach than stem cell therapies. An oral version of the 15-PGDH inhibitor has already been tested in a Phase 1 clinical trial for age-related muscle weakness without raising safety concerns, which substantially de-risks the path toward a trial focused on cartilage regeneration.

The clinical context is substantial. Osteoarthritis affects approximately one in five adults in the United States and generates an estimated 65 billion US dollars in direct healthcare costs annually. Currently approved treatments address pain management only. No drug exists that can slow or reverse the underlying cartilage damage. The only definitive intervention for late-stage osteoarthritis is surgical joint replacement. A drug or injectable that genuinely reverses cartilage loss would represent one of the largest advances in musculoskeletal medicine in a generation.

Sources: Stanford Medicine Press Release November 27, 2025 | Science (DOI: 10.1126/science.adx6649) | ScienceDaily January 2026 | ScienceAlert | Futura-Sciences